Predictive factors associated with hepatitis C antiviral therapy response.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  World Journal of Hepatology

• Publication date

  2015-06-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.4254/wjh.v7.i12.1617PMID 26140082PMCID PMC4483544
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series' [J Hepatol 73 (2020) 1170-1218].

  2022cited by this paper
• Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.

  2015cited by this paper
• Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

  2015cited by this paper
• Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

  2014cited by this paper
• Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

  2014cited by this paper
• Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C

  2014cited by this paper
• Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

  2014cited by this paper
• Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

  2014cited by this paper
• Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

  2014cited by this paper
• Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.

  2014cited by this paper
• Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study.

  2014cited by this paper
• ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

  2014cited by this paper
• Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Management of HCV transplant patients with triple therapy

  2014cited by this paper
• Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta‐analysis

  2014cited by this paper
• ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

  2014cited by this paper
• O61 EFFICACY AND SAFETY OF MK-5172 AND MK-8742 ± RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS WITH CIRRHOSIS OR PREVIOUS NULL-RESPONSE: THE C-WORTHY STUDY

  2014cited by this paper
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

  2014cited by this paper
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

  2014cited by this paper
• Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

  2014cited by this paper
• Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

  2014cited by this paper
• Importance of HCV genotype 1 subtypes for drug resistance and response to therapy

  2014cited by this paper
• Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C

  2013cited by this paper
• A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation

  2013cited by this paper
• Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.

  2013cited by this paper
• Who is more likely to respond to dual treatment with pegylated‐interferon and ribavirin for chronic hepatitis C? A gender‐oriented analysis

  2013cited by this paper
• Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3

  2013cited by this paper
• Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.

  2013cited by this paper
• Role of statins in the treatment of chronic hepatitis C virus infection.

  2013cited by this paper
• Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis.

  2013cited by this paper
• Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.

  2013cited by this paper
• Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

  2013cited by this paper
• The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007

  2012cited by this paper
• Upper Endoscopy in International Digestive Endoscopy Network 2012: Towards Upper End of Quality

  2012cited by this paper
• Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

  2012cited by this paper
• Factors that predict response of patients with hepatitis C virus infection to boceprevir.

  2012cited by this paper
• Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

  2012cited by this paper
• Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1

  2012cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.

  2011cited by this paper
• Vitamin D: An innate antiviral agent suppressing hepatitis C virus in human hepatocytes

  2011cited by this paper
• Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

  2011cited by this paper
• Boceprevir for previously treated chronic HCV genotype 1 infection.

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Telaprevir for retreatment of HCV infection.

  2011cited by this paper
• New HCV therapies on the horizon.

  2011cited by this paper
• IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population

  2011cited by this paper
• Optimal therapy in hepatitis C virus genotypes 2 and 3 patients

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Hepatitis C pharmacogenetics: State of the art in 2010

  2011cited by this paper
• IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C

  2010cited by this paper
• Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

  2010cited by this paper
• Post–liver transplant cholestatic hepatitis C: A systematic review of clinical and pathological findings and application of consensus criteria

  2010cited by this paper
• Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals.

  2010cited by this paper
• Telaprevir for previously treated chronic HCV infection.

  2010cited by this paper
• An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.

  2010cited by this paper
• IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

  2009cited by this paper
• Diagnosis, management, and treatment of hepatitis C: An update

  2009cited by this paper
• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

  2009cited by this paper
• Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

  2009cited by this paper
• Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

  2009cited by this paper
• AASLD PRACTICE GUIDELINES:diagnosis,management,and treatment of hepatitis C:an update

  2009cited by this paper
• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  2009cited by this paper
• The natural history of recurrent hepatitis C and what influences this

  2008cited by this paper
• Racial disparity in liver disease: Biological, cultural, or socioeconomic factors

  2008cited by this paper
• Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial

  2007cited by this paper
• Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence

  2007cited by this paper
• Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

  2006cited by this paper
• Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy

  2006cited by this paper
• Treating viral hepatitis C: efficacy, side effects, and complications

  2006cited by this paper
• Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.

  2006cited by this paper
• Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C

  2005cited by this paper
• Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

  2004cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• National institutes of health consensus development conference: Management of hepatitis C: 2002

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

  2002cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• European Association for the Study of the Liver

  1971cited by this paper
• Drug resistance and the response to therapy.

  1962cited by this paper

• Effectiveness of Ledipasvir-Sofosbuvir 12 Weeks After Hepatitis C Virus Genotype 1 Infection and the Factors Associated With Sustained Virologic Response: A Retrospective Study

  2024cites this paper
• Epidemiology of Hepatitis C Virus in HIV Patients from West Mexico: Implications for Controlling and Preventing Viral Hepatitis

  2024cites this paper
• Experience with HCV Detection and Molecular Genetic Characterization among Otherwise Healthy Pregnant Women and Their Partners in the Republic of Guinea

  2024cites this paper
• Molecular Epidemiology of HCV Infection among Multi-Transfused β-Thalassemia Patients in Eastern India: A Six-Year Observation

  2023cites this paper
• Value of Egy-Score in prediction of HCV response to sofosbuvir based therapy

  2023cites this paper
• Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C

  2022cites this paper
• Correlation of host factor with virological response to direct-acting antiviral treatment in hepatitis C patients

  2022cites this paper
• Tertiary Structure Prediction and Analysis of the Non-structural Protein 5B of Hepatitis C Virus Genotype 4a

  2022cites this paper
• Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.

  2022cites this paper
• Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha

  2021cites this paper
• and Study of Hepatitis C Virus infection among multi-transfused patients with inherited β-globin synthesis gene defect, in the eastern region of India

  2021cites this paper
• Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania

  2021cites this paper
• Serum Alpha-Fetoprotein, Albumin and Previous Antiviral Treatment, Can Predict Non-Response to Direct Antiviral Therapy in Egyptian Patients with Chronic Hepatitis-C

  2021influential citation
• PREVALENCE OF HEPATITIS B AND C VIRAL MARKERS AMONG APPARENTLY HEALTHY RESIDENTS OF THE SOCIALIST REPUBLIC OF VIETNAM (SOUTHERN VIETNAM)

  2021cites this paper
• Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics

  2020cites this paper
• IN SILICO ANALYSIS OF NS5B GENE OF HCV GENOTYPE 4 IN NORTH EGYPT

  2020cites this paper
• A comprehensive five-year study of Hepatitis C Virus infection and its transmission dynamics in multi-transfused β-globin defective patients in the state of West Bengal, India

  2020cites this paper
• MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing

  2020cites this paper
• Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

  2020cites this paper
• Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct‐acting antiviral therapies

  2020cites this paper
• Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan

  2020cites this paper
• Hepatitis C viral load and genotypes among Nigerian subjects with chronic infection and implication for patient management: a retrospective review of data

  2020influential citation
• A Tetra-Primer Amplification Refractory Mutation System–Polymerase Chain Reaction (T-ARMS-PCR) for Genotyping of rs8099917 & rs12979860 IL28B Polymorphisms and Its Correlation of Various Variables in Iranian HCV Patients

  2020cites this paper
• An in silico approach to analyze HCV genotype-specific binding-site variation and its effect on drug–protein interaction

  2020cites this paper
• Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C.

  2020cites this paper
• CHEMERIN IS AN INDISPENSABLE PRE-TREATMENT PREDICTOR OF SOFOSBUVIR, PEGYLATED INTERFERON-ALPHA AND RIBAVIRIN OUTCOMES IN CHRONIC HEPATITIS C EGYPTIAN PATIENTS

  2019cites this paper
• Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital

  2019cites this paper
• Direct‐acting antiviral agents in the treatment of chronic hepatitis C—Real‐life experience from clinical practices in Pakistan

  2019cites this paper
• Hepatitis C Virus Genotype 3a: Association of Core gene mutations with treatment response among patients of Peshawar

  2019cites this paper
• An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman

  2019cites this paper
• Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection

  2019cites this paper
• Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients

  2019cites this paper
• [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].

  2019cites this paper
• Suppressors of Cytokine Signaling and Protein Inhibitors of Activated Signal Transducer and Activator of Transcriptions As Therapeutic Targets in Flavivirus Infections

  2019cites this paper
• RESPONSE RATE OF SOFOSBUVIR BASED ANTIVIRAL THERAPY AMONG PATIENTS INFECTED WITH HEPATITIS C VIRUS GENOTYPE 3A

  2019cites this paper
• Hepatitis C virus genotype 3a: Predictive factors associated with treatment response in patients of Peshawar.

  2019cites this paper
• Prediction of HCV load using genotype, liver biomarkers, and clinical symptoms by a mathematical model in patients with HCV infection

  2019cites this paper
• Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.

  2019cites this paper
• Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam

  2019cites this paper
• Molecular Detection of Hepatitis C Virus amongst Patients in Five Selected Hospitals in Niger State, Nigeria

  2019cites this paper
• New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials.

  2019cites this paper
• Chronic hepatitis C: modern condition of the problem

  2019cites this paper
• Assessment of HCV viral load, genotype, liver biomarkers and clinical symptoms: Developing a mathematical model for prediction of HCV load

  2019cites this paper
• Value of Child-Turcotte-Pugh Score in Prediction of Treatment Response in “Difficult to Treat” Chronic HCV Cirrhotic Patients

  2019cites this paper
• Correlation between platelet count and outcome of chronic HCV patients treated with direct-acting antivirals

  2019cites this paper
• Hepatitis C: Host and Viral Factors Associated with Response to Therapy and Progression of Liver Fibrosis

  2018influential citation
• Direct-acting antiviral treatment for patients with hepatocellular carcinoma

  2018cites this paper
• Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world

  2018cites this paper
• Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens

  2018cites this paper
• An Increase in Expression of SOCS1 Gene with Increase in Hepatitis C Virus Viral Load

  2018cites this paper
• Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

  2018cites this paper
• Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study

  2018cites this paper
• Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting

  2018cites this paper
• 5′ UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt

  2018cites this paper
• The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C

  2018cites this paper
• Molecular targeting of antiviral drugs used against hepatitis C virus infection

  2018cites this paper
• One-step real-time PCR assay for detection and quantification of RNA HCV to monitor patients under treatment in Brazil

  2018cites this paper
• High response and re‐infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme

  2018cites this paper
• IMPACT OF HEPATIC STEATOSIS ON DISEASE COURSE IN PATIENTS WITH COMPENSATED HEPATITIS C VIRUS-RELATED CIRRHOSIS RECEIVING INTERFERON-FREE THERAPY (PARITAPREVIR, RITONAVIR, OMBITASVIR DASABUVIR AND RIBAVIRINA)

  2018cites this paper
• ASSOCIATION OF CLINICAL PARAMETERS AND INTERFERON ALPHA/BETA RECEPTOR SUBUNIT 2 IN HCV PATIENTS RESISTANT TO INTERFERON THERAPY

  2018cites this paper
• Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients.

  2018cites this paper
• Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection

  2018cites this paper
• Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral Therapy.

  2018cites this paper
• Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

  2018cites this paper
• The value of real world data in healthcare decision-making : practical applications using observational data from the National Hepatitis C Treatment Registry

  2017cites this paper
• The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.

  2017cites this paper
• Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

  2017cites this paper
• Reinventing HCV Treatment: Past and Future Perspectives

  2017cites this paper
• Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir‐containing regimens

  2017cites this paper
• Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral–Experienced Patients With Hepatitis C

  2017cites this paper
• Development of tools to investigate resistance of HCV genotype 3 to NS5A inhibitors

  2017cites this paper
• Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients

  2017cites this paper
• Simeprevir and daclatasvir for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1b and advanced liver disease

  2017cites this paper
• Identificação de polimorfismos e mutações primárias de resistência aos inibidores de protease (NS3/NS4A) no vírus da hepatite C em pacientes com hepatite C crônica monoinfectados e coinfectados pelo vírus da imunodeficiência humana

  2017cites this paper
• Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotypes 1‐4 and 6 in Myanmar: Real‐world experience

  2017cites this paper
• Cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation

  2017cites this paper
• Study of Hepatitis C virus infection at a tertiary hospital: Genotyping, risk factors and comorbidities

  2017cites this paper
• Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection

  2017cites this paper
• Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry

  2017cites this paper
• Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study

  2017cites this paper
• 25-Vitamin D levels in chronic hepatitis C infection: association with cirrhosis and sustained virologic response

  2017cites this paper
• Direct‐acting antivirals in hepatitis C virus (HCV)‐infected and HCV/HIV‐coinfected patients: real‐life safety and efficacy

  2017cites this paper
• Phylogenetic Analysis and Epidemic History of Hepatitis C Virus Genotype 2 in Tunisia, North Africa

  2016cites this paper
• Impact of IL28B Gene Polymorphism and HOMA-IR on Response to Pegylated-interferon and Ribavirin Therapy on Chronic HCV-4 Patients

  2016cites this paper
• Review article: treatment as prevention – targeting people who inject drugs as a pathway towards hepatitis C eradication

  2016cites this paper
• FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.

  2016cites this paper
• Healing livers, saving lives: Hepatitis C screening in an era of cure

  2016cites this paper
• Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.

  2015cites this paper
• The role of HCV proteins on treatment outcomes

  2015cites this paper
• Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients [version 1; peer review: 1 approved, 1 approved with reservations]

  year unknowncites this paper
• Value of Egy-Score in prediction of HCV response to sofosbuvir Value of Egy-Score in prediction of HCV response to sofosbuvir based therapy based therapy

  year unknowncites this paper